UNSPSC 51382502: Namoxyrate

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H18O2.C4H11NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38IDB6L05D, chemically known as 4-biphenylacetic acid, alpha-ethyl-, compd. with 2-(dimethylamino)ethanol (1:1) but generally known as namoxyrate, which bears US NIH Compound Identifier 14694. European Medicines Agency schedules Namoxyrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09146MIG.

UNSPSC 51382502 Namoxyrate is a Commodity code that captures state and local procurement of naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter health products distributed through authorized wholesale channels and direct-to-government supply agreements. The code sees activity across state health agencies, county health departments, and multistate cooperative purchasing alliances seeking to stock emergency response medications, community health supplies, and pharmacy benefit program products. Issuing bodies range from county health systems managing annual naloxone inventories to state health commissions structuring direct manufacturer relationships outside traditional pharmacy benefit manager arrangements, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) operating a regional cooperative vehicle spanning multiple participating states.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering vendor capabilities on direct-to-manufacturer prescription fulfillment to bypass traditional pharmacy benefit manager and group purchasing organization intermediaries. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. All three solicitations require vendor compliance with federal manufacturing and supply chain standards, E-Verify employment verification, and comprehensive insurance coverage; MMCAP imposes a 3 percent administrative fee and performance penalties for reporting and onboarding delays.